Xencor to Present at Upcoming Investor Conferences

Mittwoch, 13.11.19 22:01
Xencor to Present at Upcoming Investor Conferences
Bildquelle: Fotolia
MONROVIA, Calif. –

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in two upcoming conferences:

  • Jefferies 2019 London Healthcare Conference
    Date: Wednesday, November 20, 2019
    Presentation Time: 3:20 p.m. GMT
    Location: London
  • Piper Jaffray 31st Annual Healthcare Conference
    Date: Tuesday, December 3, 2019
    Presentation Time: 8:00 a.m. EST
    Location: New York

Live webcasts of these presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases. Currently, 14 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.



Quelle: Business Wire


News und Analysen

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS

LOS ANGELES – Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | ... | 14230

Im Fokus

Aktueller Chart
  • Erneut Vorwürfe der Financial Times?
  • Allzeithoch bei 195,75 Euro!
  • Ist die Aktie jetzt ein Schnäppchen?

ETFs ja - aber bitte mit Risikoreduktion!

ETFs ja - aber bitte mit Risikoreduktion!
Mit der BOTSI®-Strategie wird über ETFs weltweit in rund 4000 Aktien aus den bedeutendsten vier Anlageregionen investiert. Wobei durch die einzigartige, völlig prognosefrei arbeitende Steuerung der Aktienquote, risikoreduzierte Aktienmarktrenditen ermöglicht werden.
© 1994-2019 by boerse.de - Quelle für Kurse und Daten: ARIVA.DE AG - boerse.de übernimmt keine Gewähr